Number	Number		Extraction completed	Study type	Population	Population	Population Variables/	% African Americans	DRE T1 or T2+	Median Age	Median PSA (range)	Prostate volume - mear	n			
	Covidence		by:		Inclusion criteria	Exclusion criteria	Group differences					or median	Intervention:	6 cores	8 cores	10 cores
1		Abd 2011	Corinne										No. of participants			
													Primary biopsy only Location of biopsy			
			Done in Covidence										No. of participants			
			22.12.1100										Primary biopsy only Location of biopsy			
2	#774	Chamba 2014	Carinna													
2	#774	Chambo 2014	Corinne										No. of participants Primary biopsy only			
													Location of biopsy			
						f Carriers of										
			Tiago	study	neoplasia	coagulopathies	Age		19,66% 13.11% abnormal DRE	67 (43-89)	7 (0.39-2585)	42 (10-224)	No. of participants			351
					Elevated PSA (>4.0 ng/mL in men older than											
					55 years and >2.5 ng/mL in men younger											
						Individuals with urinary tract infections (whethe										
					and an annual increase in the rate of PSA levels	diagnosed at the time of										
					>0.75 ng/mL	treatment)	Race						Primary biopsy only			
																right base; right middle
																third; right apex; latero- lateral right; right
						Individuals who refused										medial; left base; left middle third; left apex;
						to provide informed written consent							Location of biopsy			latero-lateral left; left medial.
3	#924	Dell'Atti 2015	Corinne										No. of participants			
													Primary biopsy only Location of biopsy			
					TRUS guided PBx, 12, 14 and 18 cores, between											
					Sept 2007 to May 14 in the University Hospital S.	. Patient still on										
			Ingrid	Retrospectivr study?	Anna. Ferrara, Italy						63,4	6,8 48,	3 No. of participants Primary biopsy only			
													, crops, omy			
													Location of biopsy			
4	#083	Ekin 2015	Carinna													
4	#983	EMII 2015	Corinne										No. of participants Primary biopsy only			
													Location of biopsy			
			Kal	Prospective	PSA 2.5ng/ml or higher	>70 years with PSA <10			T1 = 25		63,33 9	,84 45,	No. of participants			
					Abnormal DRE	<10 years life expectance	у		T2 = 44				Primary biopsy only			
						PSA >50							Location of biopsy			
5	#1218	HerranzAmo 2010	Corinne										No. of participants Primary biopsy only			
													Location of biopsy			
			Phil	Randomized prospective	e Initial Biopsy	UTI or acute prostatitis	10 cores vs 6 cores		0 T1		65,8	6,7 45,	7 No. of participants	164		151
					PSA 3.5-20ng/ml T1c	Catheter previous TURP							Primary biopsy only Location of biopsy			
6	#796	Chen 2016	Corinne										No. of participants			
	(see complication															
	s excel)												Primary biopsy only			
													Location of biopsy			

					_	-								
					Abnormal digital rectal									
					examination and/ or T-									
			Tiago	Retrospective study	PSA ≥ 4 ng/ml					73 (41-90)		19 54.5 ± 38.3 ml	No. of participants	40
					no previous biopsy.								Primary biopsy only	
/													Timary biopsy omy	
														1 core from the base, 1
/														core from the mid gland
/														2 cores from the apex and 1 core from the
/														transition zone (TZ) on
													Location of biopsy	both sides of the gland
#	788	Chen 2012	Corinne										No. of participants	
													Primary biopsy only	
													Location of biopsy	
					Men underwent 12 core									
					biopsy in the clinic, with									
				Randomized controlled		Danie de la constante								
			Ingrid	trial?	clinic or PSA > 10 with normal DRE and TRUS.	Previously underwent highest or TUR-P	Age		0 147 (57.4%)?		65	10,6	38,5 No. of participants	
			Ingrid		Men aged 50 - 80		PSA		2 2 3 (371.79)				Primary biopsy only	
			I											
						with catheter	DRE						Location of biopsy	
			I			acute urinary infection								
			I			last 3 months	PV							
#	854	Cormio 2014	Corinne										No. of participants	
(9	see													
	complication		I											
S	excel)												Primary biopsy only	
													Location of biopsy	
					Consecutive patients									
					referenced for 1st biopsy									
					between February 2008 to November 2010,									
					because of increased									
					PSA (>=4 ng/ml) and/or									
					abnormal DRE	patients diagnosed with								
			Tiago		(DRE)	HG-PIN or ASAP				67 (43-90)	7.20 (0.6–1000)	50 (15–200)	No. of participants	
													Drimary bioncy only	
													Primary biopsy only	
													Primary biopsy only	
													Primary biopsy only	
													Primary biopsy only	
													Primary biopsy only	
													Primary biopsy only	
													Primary biopsy only  Location of biopsy	
													Location of biopsy	
#	1992	Elshafei 2014	Corinne										Location of biopsy  No. of participants	
#	1992	Elshafei 2014	Corinne										Location of biopsy  No. of participants  Primary biopsy only	
#	992	Elshafei 2014	Corinne										Location of biopsy  No. of participants	
#	992	Elshafei 2014	Corinne										Location of biopsy  No. of participants  Primary biopsy only	
Á	<del>1</del> 992	Elshafei 2014	Corinne			Patients with less than							Location of biopsy  No. of participants  Primary biopsy only	
#	<del>1</del> 992	Elshafei 2014	Corinne			12 cores and more than							Location of biopsy  No. of participants  Primary biopsy only	
t.	992	Elshafei 2014	Corinne		Patients who had initial	12 cores and more than 14, or if 2 additional							Location of biopsy  No. of participants  Primary biopsy only	
*	992	Elshafei 2014	Corinne		Patients who had initial EPBx with 12 and 14 core	12 cores and more than 14, or if 2 additional cores were retrieved							Location of biopsy  No. of participants  Primary biopsy only	
#	992	Elshafei 2014	Corinne	Retrospectiv study		12 cores and more than 14, or if 2 additional cores were retrieved	Standard risk of PCa	437 (18%)		12 core: 64.6		5,05	Location of biopsy  No. of participants  Primary biopsy only	
#	992	Elshafei 2014		Retrospectiv study	EPBx with 12 and 14 core	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other		437 (18%)		12 core: 64.6		5,05	No. of participants Primary biopsy only Location of biopsy	
*	992	Elshafei 2014		Retrospectiv study	EPBx with 12 and 14 core scheme	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other		437 (18%)		12 core: 64.6		5,05	No. of participants Primary biopsy only Location of biopsy	
4.	992	Elshafei 2014		Retrospectiv study	EPBx with 12 and 14 core	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other		437 (18%)		12 core: 64.6		5,05	No. of participants Primary biopsy only Location of biopsy	
44	992	Elshafei 2014		Retrospectiv study	EPBx with 12 and 14 core scheme  Only patients with	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other than the apex.		437 (18%) 77 (149%)		12 core: 64.6 14 core: 62.7			No. of participants Primary biopsy only Location of biopsy  37,7 No. of participants	
	992	Elshafei 2014		Retrospectiv study	EPBx with 12 and 14 core scheme  Only patients with available data were	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other than the apex.	1. Standard risk of PCa						No. of participants Primary biopsy only Location of biopsy	
2	992	Elshafei 2014		Retrospectiv study	EPBx with 12 and 14 core scheme  Only patients with available data were	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other than the apex.	1. Standard risk of PCa						No. of participants Primary biopsy only Location of biopsy  37,7 No. of participants	
3	1992	Elshafei 2014		Retrospectiv study	EPBx with 12 and 14 core scheme  Only patients with available data were	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other than the apex.	1. Standard risk of PCa						No. of participants Primary biopsy only Location of biopsy  37,7 No. of participants	
3	1992	Elshafei 2014		Retrospectiv study	EPBx with 12 and 14 core scheme  Only patients with available data were	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other than the apex.	1. Standard risk of PCa						No. of participants Primary biopsy only Location of biopsy  37,7 No. of participants  40,7 Primary biopsy only	
1	1992	Elshafei 2014		Retrospectiv study	EPBx with 12 and 14 core scheme  Only patients with available data were	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other than the apex.	1. Standard risk of PCa						No. of participants Primary biopsy only Location of biopsy  37,7 No. of participants	
		Elshafei 2014 Filson 2016		Retrospectiv study	EPBx with 12 and 14 core scheme  Only patients with available data were	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other than the apex.	1. Standard risk of PCa						No. of participants Primary biopsy only Location of biopsy  37,7 No. of participants  40,7 Primary biopsy only	
			Ingrid	Retrospectiv study	EPBx with 12 and 14 core scheme  Only patients with available data were	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other than the apex.	1. Standard risk of PCa						No. of participants Primary biopsy only Location of biopsy  37,7 No. of participants  40,7 Primary biopsy only Location of biopsy  No. of participants Primary biopsy only	
			Ingrid	Retrospectiv study	EPBx with 12 and 14 core scheme  Only patients with available data were	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other than the apex.	1. Standard risk of PCa						Location of biopsy  No. of participants  Primary biopsy only  Location of biopsy  37,7 No. of participants  40,7 Primary biopsy only  Location of biopsy  No. of participants	
			Ingrid		EPBx with 12 and 14 core scheme  Only patients with available data were	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other than the apex.	1. Standard risk of PCa						No. of participants Primary biopsy only Location of biopsy  37,7 No. of participants  40,7 Primary biopsy only Location of biopsy  No. of participants Primary biopsy only	
			Ingrid	This study doesn't	EPBx with 12 and 14 core scheme  Only patients with available data were	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other than the apex.	1. Standard risk of PCa						No. of participants Primary biopsy only Location of biopsy  37,7 No. of participants  40,7 Primary biopsy only Location of biopsy  No. of participants Primary biopsy only Location of biopsy  No. of participants Primary biopsy only Location of biopsy	
			Ingrid		EPBx with 12 and 14 core scheme  Only patients with available data were	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other than the apex.	1. Standard risk of PCa						No. of participants Primary biopsy only Location of biopsy  37,7 No. of participants  40,7 Primary biopsy only Location of biopsy  No. of participants Primary biopsy only Location of biopsy  No. of participants Primary biopsy only Location of biopsy  No. of participants	
			Ingrid	This study doesn't	EPBx with 12 and 14 core scheme  Only patients with available data were	12 cores and more than 14, or if 2 additional cores were retrieved e from locations other than the apex.	1. Standard risk of PCa						No. of participants Primary biopsy only Location of biopsy  37,7 No. of participants  40,7 Primary biopsy only Location of biopsy  No. of participants Primary biopsy only Location of biopsy  No. of participants Primary biopsy only Location of biopsy	

13	#1103	Ghafoori 2015	Corinne								No. of participants	
	(see											
	complication											
	s excel)										Primary biopsy only Location of biopsy	
											Location of biopsy	
				Randomized clinical tria		pas with sympt/sign of						
			Ingrid	study	Pas with PSA elevation	infections	0	58.4 in 6 core group		8,7	No. of participants	X (60)
					Abnormal DRA	Previous biopsy		57.6 in 12 core group		7,9	Primary biopsy only	
						Prostatic TUR due to BPH		58.7 in 18 core group		8,6	Location of biopsy	Base, middle and apex on both side
											,	
						Receiving antibiotic						
14	#91	Irani 2013	Corinne			treatment					No. of participants	
			Comme								Primary biopsy only	
											Location of biopsy	
						5 alpha-reductase						
			Phil	Randomized	initial Biopsy	inhibitor		63,	1	7 47.6 mls	No. of participants	
					PSA 3-20ng/ml			62.8 in 12 core group	7.5 in 12 core group	48.3 mls in 12 core group	Primary biopsy only	
					T1c or possible T2a			63.4 in 20 core group	6.6 in 20 core group	46.8 mls in 20 core group	Location of highsy	
											Eccution of Biopsy	
15	#1343	Jiang 2016	Corinne								No. of participants	
											Primary biopsy only	
											Location of biopsy	
			Tiago	Not related to PICO 1							No. of participants	
											Primary biopsy only Location of biopsy	
											Eccution of Biopsy	
16	#1560	Leucona 2011	Corinne								No. of participants	
											Primary biopsy only Location of biopsy	
											Location of biopsy	
							group A: 25 (16.8)					
			Tiaga	Prospective randomized trial	PSA level >2.5 ng/mL	Previous prostate biopsy	suspicious or malignant	group A: 65 1 (45_82)	group A: 9.4 (2.2–46)	group A: 47.4 (11–220)	No of participants	151 (group B)
			Tiago	Criai	r 3A level >2.3 lig/lilL	oi suigery	mangnant	group A. 03.1 (43–62)	group A. 3.4 (2.2-40)	group A. 47.4 (11-220)	NO. OF PARTICIPARTS	151 (group b)
						Previous diagnosis of prostate cancer	group A: 124 (83.2) benign	group B: 63.4 (40-81)	group R: 0.2 (2.6-48)	group B: 51.5 (10–194)	Driman, biance anh	151
						prostate carreer	group B: 36 (23.8)	group b. 03.4 (40 01)	group b. 3.2 (2.0 40)	group b. 31.3 (10 134)	Filliary biopsy offig	151
							suspicious or					
						History of urinary retention	malignant				Location of biopsy	lateral peripheral zone
						recention					Location of biopsy	lateral peripheral zone
						Previous histological						
						evidence of prostatitis and confirmed urinary	group B: 115 (76.2) benign					
						tract infection	Je.ng.					
				Prospective randomized	i							
33	#4164	Leitao 2017	Tiago	trial	suspicious DRE	active UTI;		67 (62-72)	7.70 (.69-11.24)	48 (35-66)	No. of participants	219 (48%)
						de constant de contract de con						
			I		elevated serum PSA	documented previous pathologic prostatitis					Primary biopsy only	
					TRUS imaging findings	F					J Diopsy Only	
			I		suspicious for prostate	history of urinary						
	Nov search		I		cancer	retention recent lower urinary					Location of biopsy	
						tract surgery						
												Group B: 219. Group A:
												not specified. Total 237
			Corinne								No. of participants	patients with 8-12 cores

17	#1582	Leibovici 2013	Corinne	Prospective randomized study	Suspicious DRE, elvated PSA or TRUS supicious imaging		Group A: Bx according Vienna Nomogram (number cores dependant of age, prostate volume and PSA). Group B: 10 cores bx. Primary endpoint: cancer detection	Not specified	Not specified	Group A: 68 (63-73). Group B: 66 (61-71) p: .010 (NS)	Group A: 7.90 (5.77- : 11.78). Group B: 7.60 (5.63-11) p= .349 (NS)	Group B: 46 (35-68) p=	Primary biopsy only Location of biopsy No. of participants Primary biopsy only		
													Location of biopsy		
			Ingrid		All patients in the center undergoing prostate biopsy 2007	Pas with CaP			0	63 (48-82)	6.7 (0.5 - 156.0)	57 (16 - 273)	No. of participants		
													Primary biopsy only		
													Location of biopsy		
18	#1673	Lughezzani 2010	Corinne										No. of participants		
													Primary biopsy only Location of biopsy		
			Tiago	systematic review	This study doesn't answer to PICO 1								No. of participants Primary biopsy only		
													Location of biopsy		
19	#1776	Miyoshi 2014	Corinne										No. of participants		
													Primary biopsy only Location of biopsy		
			Tiago	Excluded (transperineal biopsies)- not for PICO 1									No. of participants Primary biopsy only		
													Location of biopsy		
20	#1783	Mohammed 2016	Corinne										No. of participants		
													Primary biopsy only Location of biopsy		
			Tiago	Retrospective study	Positive TRUS biopsy (Gleason >= 6)	Negative TRUS biopsy			group A: 26 (18.2 %) abnormal	group A: 59.6 ± 6.6	group A: 9 ± 5.1	group A: 24.6 ± 5.7	No. of participants	143	
						Metastatic prostate cancer at the time of			group B: 42 (29.4 %)						
						diagnosis High-grade prostatic intraepithelial neoplasia	1		abnormal	group B: 61 ± 6.2	group B: 8.5 ± 4.6	group B: 23.6 ± 6.2	Primary biopsy only		
						(PIN)							Location of biopsy		
21	#1882	Nomikos 2011	Corinne										No. of participants Primary biopsy only Location of biopsy		
					Men underwent TRUS prostate biopsy in the										
			Ingrid	Retrospectiv Reviewed	clinic, between april 2007 - august 2009.	age of 75 and older				6	55,4	5,2 42,5	No. of participants		243 (64.11%)
					abnormal DRE	PSA over 20 ng/mL				6	56,1	5,2 46,	Primary biopsy only		lat.bas, lat mid, apex, parasagittal mid-zone, parasagital base on both
					elevated PSA								Location of biopsy		side
22	#1931	Ouzaid 2013	Corinne										No. of participants		
													Primary biopsy only Location of biopsy		
													o. diopsy		

				patients who had a 1st	and the American distribution of the Control of the						
				positive 21-core biopsy followed by radical	Finasteride, Dutasteride						
			Retrospective Cohort			6-core- T1: 240 (81%)					
			Tiago study	2001 and 2009.	hormonal therapy		63 (42-76)	10.25 (1.1-67)		No. of participants	
			,		.,		·	, ,			
						12-core T1: 333 (82,8);					
						T2+: 69 (17,2%)				Primary biopsy only	
						21-core T1: 42 (98%)					
						;T2+: 1 82%)				Location of biopsy	standard sextant biopsies
						,12-12-02/01				Location of biopsy	standard sextant biopsies
23	#1968	Park 2010	Corinne							No. of participants	
										Primary biopsy only	
										Location of biopsy	
			n	d DCA - 2/1	Daniel Birani 42 40				4. 42		
			Phil Prospective randomized	PSA >SIIg/IIII	Repeat Biopsy 12 core vs 18 core		6	8 7,		No. of participants	
										Primary biopsy only	
										Location of biopsy	
24	#2124	Rodriguez-	Coden							No. of any or	
24	#2124	Covarrubias 2011	Corinne							No. of participants	
										Primary biopsy only	
										Location of biopsy	
			Prospective randomized	i			group A: 64.50 ± 7.26	group A: 8.89 ± 3.83	group A: 53.01 ± 30.25		
			Tiago trial	Age 45 to 75 years	Previous PCa diagnosis	group A: 12 abnormal	(41-80)	(3.23-19.80)	(16.00-219.00)	No. of participants	
					PSA greater than 20		group B: 65.08 ± 6.82	group B: 8.40 ± 3.60	group B: 54.11 ± 27.59		
				PSA 4 to 20 ng/ml	ng/ml	group A: 63 normal	(50–79)	(0.86–18.00)	(13.60-147.00)	Primary biopsy only	
				No previous biopsy	Clinical stage T3 or T4	group B: 10 abnormal				Location of biopsy	
					Previous 5 alfa-reductase						
					inhibitor use (finasteride						
					or dutasteride) or androgen deprivation						
					therapy	group B: 65 normal					
25	#2210	Scattoni 2014	Corinne			8.004 2.00				No. of participants	
										Primary biopsy only	
										Location of biopsy	
				Written litteratur about							
			Ingrid Critical Litteratur Review	prostatebiopsy Jan05 - w Jan14	Screening					No. of participants	
			Systematic review							Primary biopsy only	
			.,							Location of biopsy	
26	#2211	Scattoni 2010	Corinne							No. of participants	
										Primary biopsy only	
										Location of biopsy	
			Ingrid Systematic review							No. of participants	
										Primary biopsy only	
										Location of biopsy	
27	#2242	C									
27	#2213	Scattoni 2010	Corinne							No. of participants	
										Primary biopsy only Location of biopsy	
										Location of biopsy	
			Systematic review. We								
			Ingrid      have a updatet version							No. of participants	
										Primary biopsy only	
										Location of biopsy	
			İ								

20	H2200	Tanaka 2015	Carina									No of continuous			
28	#2389	Tanaka 2015	Corinne									No. of participants			
												Primary biopsy only Location of biopsy			
												Location of biopsy			
					Acute or chronic										
			Tiago	Abnormal PSA	prostatitis				group A: 71 (22-94)	group A: 7.1 (0.3-16.9)	20) group A: 33.2 (6-176)	No. of participants		169	331 237
				41 1005					p. 70 (22 00)	D 5 0 (0 2 02 C)	D 20 0 (5 475)				
				Abnormal DRE	Urinary retention				group B: 70 (22-89)	group B: 5.8 (0.3-83.6)	group B: 38.8 (6-176)	Primary biopsy only			
				Abnormal findings by						group C: 10.1 (0.6-					
				transrectal ultrasound.	Urinary tract infection				group C: 73 (49-94)	16.920)	group C: (28.1 (10-155)	Location of highsy			
					Indwelling urinary				8.000 0.00 (.000.)		8. 10 p o (2012 (20 200)	Location of biopsy			
					catheter										
29	#2460	Tsivian 2012	Corinne									No. of participants			
												Primary biopsy only			
												Location of biopsy			
				Pas opr RARP 1990-2007.											
			Ingrid Retrospective study	859 records	None?	Prostate = 40g</td <td>78 (17.9)</td> <td></td> <td>60</td> <td>0.4</td> <td>5,5 <!--= 40 g</td--><td>No. of participants</td><td>6 - 9 cores</td><td></td><td>10 - 20 cores</td></td>	78 (17.9)		60	0.4	5,5 = 40 g</td <td>No. of participants</td> <td>6 - 9 cores</td> <td></td> <td>10 - 20 cores</td>	No. of participants	6 - 9 cores		10 - 20 cores
			g.u							-,-	-,- , 8	Troi or participants	0 3 00/03		
						Prostate > 40 g			62	2,4	5,8 > 40 g	Primary biopsy only			
												Location of biopsy			
			comprehensive Medlin												
			search/ review. Exclude												
			from data extraction bu												
			we check the comment												
			we can use it for the te	ct											
30	#2490	Ukimura 2013	Corinne of the guidelines									No. of participants			
												Primary biopsy only			
												Location of biopsy			
												Location of biopsy			
			Systematic review data												
			Kal excluded elsewhere									No. of participants			
												Driman, biance only			
												Primary biopsy only			
												Location of biopsy			
				Florestand DCA between											
				Elevated PSA between											
				<ol><li>2.5- 20 ng/MI, regardless of abnormal finding on</li></ol>		Cores 10 versus 12.									
				digital rectal		Prostate volume <40ml									
				examination and		versus <40ml. PSA 2.5-				/- 10 cores group:10.5					
			Randomized prospective			4.0 versus 4.1-10 versus				.4 +/13.3. 12 cores group	: +/22.4. 12 cores group:				
31	#2685	Yoon 2012	Corinne study	ultrasonography		10.1-20	Only asian patients	NA	+/-10.2. p .053	12.1 +/-20.1. p .411	42.0 +/-4.9. p .723	No. of participants			351
												Primary biopsy only			Not specified
															Sextant+ lateral
															peripheral zone biopsy
															cores. apex of the lateral
															peripheral zone added to
			1												10 cores
												Location of biopsy			
			Kal Prospective RT	PSA 2.5 to 20					62	2,9 10.9-15.3		No. of participants			351
			1									Primary biopsy only			
			1												
			1									Location of biopsy			Sextant technique
												Escation of biopsy			
32	<b>#2712</b>	Zavaski 2014	Corinne									No. of participants			
												Primary biopsy only			
			1									Location of biopsy			
			This study doesn't												
			Tiago answer to PICO 1									No. of participants			
			1									Primary biopsy only			
												Location of biopsy			
			I .												

Column   C	lb.o.u	Number	Author wasn			T		1		T	1			1		
State   Stat	Number		Author, year													
Part				12 cores 13	3 cores	14 cores	16 cores	18 cores	20 cores	21 cores	overall	Outcomes (%, N), control, overall	6 cores	8 cores	10 cores	12 cores
Part																
Part			Abd 2011													
No.   1																
Marie																
March   Marc																
Part																
Manual Property																
Part																
And of the second secon	,	#774	Chambo 2014													
Manual Property of the Control of			C11011100 2021									No /% of prostate cancer Gleason score 6				
No.   Section													i			
Mail													i			
## 1																
## 1																
Marie   Mari				351			351	L				Positive pick-up rate (overall cancer diagnosis)			10	2
March   Marc																
March   Marc																
March   Marc																
March   Marc																
Major   Majo																
March   Marc																
March   Marc																
March   Marc																
Mart   1995												No./% of prostate cancer Gleason score 6			3.	5
Mary																
Mart   1972																
Manual Part																
March   Marc				right hase: right middle												
Manual Part																
Part																
Mary																
Mark																
Part																
ACTAIL  AND ADDRESS AND ADDRES				middle third; left apex.												
April   Apri							third; left apex.								6	7
Supplied and process of the control of the contro																
No. 10   10   10   10   10   10   10   10		#924	Dell'Atti 2015													
No. 17   N																
The second of th																
No. 7 of prostate cancer (Season score 6  Aport, middle and base of each lateral flow of each lateral flow of each lateral flow of each lateral flow of the Tarrollon zone (TT)  Aport, middle and base of each lateral flow of the Tarrollon zone (TT)  Tarrollon zone (TT)  Aport, middle and base of each lateral flow of the Tarrollon zone (TT)  Tarrollon zone (TT)  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport definition part power prostate cancer floward score Zone Aport above  Aport of contacts part floward score Zone Aport above  Aport of prostate cancer floward score Zone Aport above  Aport floward cancer floward score Zone Aport above  Aport flo												No. of 76 of positive cores				
No. 7 of prostate cancer (Season score 6  Aport, middle and base of each lateral flow of each lateral flow of each lateral flow of each lateral flow of the Tarrollon zone (TT)  Aport, middle and base of each lateral flow of the Tarrollon zone (TT)  Tarrollon zone (TT)  Aport, middle and base of each lateral flow of the Tarrollon zone (TT)  Tarrollon zone (TT)  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport definition part power prostate cancer floward score Zone Aport above  Aport of contacts part floward score Zone Aport above  Aport of prostate cancer floward score Zone Aport above  Aport floward cancer floward score Zone Aport above  Aport flo																
No. 7 of prostate cancer (Season score 6  Aport, middle and base of each lateral flow of each lateral flow of each lateral flow of each lateral flow of the Tarrollon zone (TT)  Aport, middle and base of each lateral flow of the Tarrollon zone (TT)  Tarrollon zone (TT)  Aport, middle and base of each lateral flow of the Tarrollon zone (TT)  Tarrollon zone (TT)  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport definition part power prostate cancer floward score Zone Aport above  Aport of contacts part floward score Zone Aport above  Aport of prostate cancer floward score Zone Aport above  Aport floward cancer floward score Zone Aport above  Aport flo																
No. 7 of prostate cancer (Season score 6  Aport, middle and base of each lateral flow of each lateral flow of each lateral flow of each lateral flow of the Tarrollon zone (TT)  Aport, middle and base of each lateral flow of the Tarrollon zone (TT)  Tarrollon zone (TT)  Aport, middle and base of each lateral flow of the Tarrollon zone (TT)  Tarrollon zone (TT)  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport definition part power prostate cancer floward score Zone Aport above  Aport of contacts part floward score Zone Aport above  Aport of prostate cancer floward score Zone Aport above  Aport floward cancer floward score Zone Aport above  Aport flo																
No. 7 of prostate cancer (Season score 6  Aport, middle and base of each lateral flow of each lateral flow of each lateral flow of each lateral flow of the Tarrollon zone (TT)  Aport, middle and base of each lateral flow of the Tarrollon zone (TT)  Tarrollon zone (TT)  Aport, middle and base of each lateral flow of the Tarrollon zone (TT)  Tarrollon zone (TT)  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport the prostate cancer floward score Zone Aport above  Aport definition part power prostate cancer floward score Zone Aport above  Aport of contacts part floward score Zone Aport above  Aport of prostate cancer floward score Zone Aport above  Aport floward cancer floward score Zone Aport above  Aport flo																
Aper, middle and base of each lateral laber and base of textures and the each lateral laber and base of each lateral laber and base of textures and lateral laber and lateral lateral laber and lateral laber and lateral latera				Х		Х		Х			135					
Apex, model and bases of each lateral lobe*   each lateral lobe*   family significant cancers (Glesson score 7 or above												No./% of prostate cancer Gleason score 6				
Apex, model and bases of each lateral lobe*   each lateral lobe*   family significant cancers (Glesson score 7 or above						Aney middle and hase o	f	Aney middle and hase of	f							
A STATE   ST				Apex, middle and base of												
No. of so positive cores PSSS Alta 2015 PSSS Alta 2												No. of clinically significant cancers (Gleason score 7 or above				
PRESS   Name 2015   Procedure pack up care (procedure cancer diagonals)																!
No. of dinically significant cancers (Glesson score 7 or above No. or % of positive pick-up rate (overall cancer diagnosis)		#983	Ekin 2015													
A51  A521  A521  A521  A532  A534  A																
451 Positive pick-up rate (overall cancer diagnosis)  1.8ft Apex/mid/base, micd + lat + ant  47218 HerranzAmo 2010  47218 AlerranzAmo 2010  47228 AlerranzAmo 2010  47238 Aler																
Bas Apex/mid/base, med = lat + ant   No. of clinically significant cancers (Glesson score 7 or above												No. or % of positive cores				
Bar Aper/md/base, med = lat + ant   No. /f of prostate cancer Gleason score 6						AF-	1					Desitive niek up rote (a	I			
LSR Aper/mid/base, med + lat + ant    HerranzAmo 2010   Positive pick- up rate (overall cancer diagnosis)						45:	1					Positive pick-up rate (overall cancer diagnosis)				
LSR Aper/mid/base, med + lat + ant    HerranzAmo 2010   Positive pick- up rate (overall cancer diagnosis)																
LSR Aper/mid/base, med + lat + ant    HerranzAmo 2010   Positive pick- up rate (overall cancer diagnosis)												No./% of prostate cancer Gleason score 6				
March   Marc						L&R Apex/mid/base,						, p	i			
#218 HerranzAmo 2010  #2218 HerranzAmo 2010  #2218 PermanzAmo 2010  #2218 Positive pick-up rate (cleason score 6  #2218 Positive pick-up rate (overall cancer diagnosis)  #222 Positive pick-up rate (overall cancer diagnosis)  #222 Positive pick-up rate (overall cancer diagnosis)  #223 Positive pick-up rate (overall cancer diagnosis)  #223 Positive pick-up rate (overall cancer diagnosis)  #224 Positive pick-up rate (overall cancer diagnosis)  #225 Positive pick-up rate (overall cancer diagnosis)  #225 Positive pick-up rate (overall cancer diagnosis)  #226 Positive pick-up rate (overall cancer diagnosis)  #226 Positive pick-up rate (overall cancer diagnosis)  #227 Positive pick-up rate (overall cancer diagnosis)  #228 Positive pick-up rate (overall cancer diagnosis)  #227 Positive pick-up rate (overall cancer diagnosis)  #228 Positive pick-up rate (overall cancer diagnosis)  #228 Positive pick-up rate (overall cancer diagnosis)  #229 Positive pick-up rate (overall cancer diagnosis)  #220 Positive pick-up rate (overall cancer diagnosis)												No. of clinically significant cancers (Gleason score 7 or above	I			
#2218 HerranzAmo 2010  Positive pick-up rate (overall cancer Gleason score 7 or above No. or % of postate cancer Gleason score 7 or above No. or % of postate cancer Gleason score 7 or above No. or % of postative pick-up rate (overall cancer diagnosis)  #238 Positive pick-up rate (overall cancer diagnosis)  #24 (25%)  #25 No. of clinically significant cancers (Gleason score 6 No. or % of postate cancer Gleason score 7 or above No. or % of positive pick-up rate (overall cancer diagnosis)  #296 Chen 2016  #296 Chen 2016  #296 Complication sexuel)  #298 No. of clinically significant cancers (Gleason score 6 No. or % of positive pick-up rate (overall cancer diagnosis)  #298 No. of clinically significant cancers (Gleason score 6 No. or % of positive pick-up rate (overall cancer diagnosis)  #298 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive pick-up rate (overall cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive pick-up rate (overall cancer Gleason score 7 or above No. or % of clinically significant cancers (Gleason score 7 or above No. or % of clinically significant cancers (Gleason score 7 or above No. or % of clinically significant cancers (Gleason score 7 or above No. or % of clinically significant cancers (Gleason score 7 or above No. or % of clinically significant cancers (Gleason score 7 or above No. or % of clinically significant cancers (Gleason score 7 or above No. or % of clinically significant cancers (Gleason score 7 or above No. or % of clinically significant cancers (Gleason score 7 or above No. or % of clinically significant cancers (Gleason score 7 or above No. or % of above No. or % of clinically significant cancers (Gleason score 7 or above No. or % of above												No. or % of positive cores				
No./% of prostate cancer Gleason score 6		#1218	HerranzAmo 2010									Positive pick-up rate (overall cancer diagnosis)				
No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No. or % of positive cores  No. or % of positive cores  No. of clinically significant cancer diagnosis)  No./% of prostate cancer Gleason score 6  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above												No./% of prostate cancer Gleason score 6				
Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  No. or % of positive cores  See complicatio ns excel)  No./% of prostate cancer Gleason score 6  No. or % of positive cores  No./% of prostate cancer diagnosis)																
No. /% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  #796 (see complicatio ns excel) No. /% of prostate cancer Gleason score 6 No. or % of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above												No. or % of positive cores				
No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  #796 (see complicatio ns excel)  No./% of prostate cancer Gleason score 6  No. or % of prostate cancer diagnosis)													I			
No. /% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  #796 (see complicatio ns excel) No. /% of prostate cancer Gleason score 6 No. or % of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above												Desitive niek up rate (a	41 (250/)		4F /20 99/\	
No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  #796 (see complicatio ns excel)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above												POSITIVE PICK-up rate (overall cancer diagnosis)	41 (25%) 		45 (29.8%)	
No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  #796 (see complicatio ns excel)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above																
No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  #796 (see complicatio ns excel)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above												No./% of prostate cancer Gleason score 6				
No. or % of positive cores  #796 (see complicatio ns excel)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above																
#796   Positive pick-up rate (overall cancer diagnosis)   (see complicatio   No./% of prostate cancer Gleason score 6   No. of clinically significant cancers (Gleason score 7 or above																
(see complicatio ns excel)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above		#796	Chen 2016													
complicatio ns excel) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above																
ns excel)  No. /% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above																
No. of clinically significant cancers (Gleason score 7 or above												No./% of prostate cancer Gleason score 6				
No. or % of positive cores																
												No. or % of positive cores				

			409		Positive pick-up rate (overall cancer diagnosis)	181 (44.3%)
			103		rositive pick-up rate (overall caricer diagnosis)	101 (44.370)
			409		No./% of prostate cancer Gleason score 6	
			3 midline punctures, 6			
			parasagittal midline			
			punctures, and 4 lateral punctures		No. of all all all all all all all all all al	
			punctures		No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores	
7	#788	Chen 2012			Positive pick-up rate (overall cancer diagnosis)	
,	#700	CHCH 2012			No./% of prostate cancer Gleason score 6	
					No. of clinically significant cancers (Gleason score 7 or above	
					No. or % of positive cores	
			923		Positive pick-up rate (overall cancer diagnosis)	243 (27.4%)
			lateral base, mid-gland		No./% of prostate cancer Gleason score 6	153 (60.5%)
			lateral base, mid-gland		No. of clinically significant cancers (Gleason score 7 or above	100 (57+43) (39.5%)
			and apex		INO. OF CHINICALLY SIGNIFICANT CANCERS (Gleason score / or above	100 (5/+43) (39.5%)
					No. or % of positive cores	1 - 12 (3.2%)
9	#854	Cormio 2014			Positive pick-up rate (overall cancer diagnosis)	1 12 (5)279
	(see				Tostite plan aprate (ore all carries alughosis)	
	complicatio					
	ns excel)				No./% of prostate cancer Gleason score 6	
					No. of clinically significant cancers (Gleason score 7 or above	
					No. or % of positive cores	
				1021	Docitive pick up rate (everall capear diagnosis)	250 65
				1081	Positive pick-up rate (overall cancer diagnosis)	358 66
						358 66
				1081	Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6	358 66
						358 66
				1081 traditional sextant (6-		358 66
				traditional sextant (6-core), 4 lateral peripheral		358 66
				traditional sextant (6-core), 4 lateral peripheral (10-core), 4 paramedian		358 66
				traditional sextant (6-core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and		358 66
				traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No./% of prostate cancer Gleason score 6	358 66
				traditional sextant (6-core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and	No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above	358 66
11	#992	Elshafei 2014		traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores	358 66
11	#992	Elshafei 2014		traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. /% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis)	358 66
11	#992	Elshafei 2014		traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6	358 66
11	#992	Elshafei 2014		traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above	358 66
11	#992	Elshafei 2014		traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6	358 66
11	#992	Elshafei 2014		traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above	358 66
11	#992	Elshafei 2014		traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above	358 66
11	#992	Elshafei 2014		traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above	358 66
11	#992	Elshafei 2014		traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above	358 66
11	#992	Elshafei 2014		traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores	358 66
11	#992	Elshafei 2014	2421 532	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above	358 66
11	#992	Elshafei 2014	2421 532	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores	
11	#992	Elshafei 2014	2421 532	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores	
11	#992	Elshafei 2014	2421 532	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores	
11	#992	Elshafei 2014	2421 532	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)	
11	#992	Elshafei 2014	2421 532	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores	
11	#992	Elshafei 2014		traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)	
11	#992	Elshafei 2014	2 Apex, 2 Middle and 2	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)	
11	#992	Elshafei 2014	2 Apex, 2 Middle and 2 Bas on both sides +n2	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)	
11	#992	Elshafei 2014	2 Apex, 2 Middle and 2	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  3350 Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6	
11	#992	Elshafei 2014	2 Apex, 2 Middle and 2 Bas on both sides +n2 2 Apex, 2 Middle and 2 extra core from the	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  3350 Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6	41,85%
11		Elshafei 2014 Filson 2016	2 Apex, 2 Middle and 2 Bas on both sides +n2 2 Apex, 2 Middle and 2 extra core from the	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  3350 Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6	
			2 Apex, 2 Middle and 2 Bas on both sides +n2 2 Apex, 2 Middle and 2 extra core from the	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. /% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  No. of clinically significant cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6	41,85%
			2 Apex, 2 Middle and 2 Bas on both sides +n2 2 Apex, 2 Middle and 2 extra core from the	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  3350  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above  No. of positive cores  Positive pick-up rate (overall cancer diagnosis)	41,85%
			2 Apex, 2 Middle and 2 Bas on both sides +n2 2 Apex, 2 Middle and 2 extra core from the	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. /% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  No. of clinically significant cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6	41,85%
			2 Apex, 2 Middle and 2 Bas on both sides +n2 2 Apex, 2 Middle and 2 extra core from the	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores	41,85%
			2 Apex, 2 Middle and 2 Bas on both sides +n2 2 Apex, 2 Middle and 2 extra core from the	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis)	41,85%
			2 Apex, 2 Middle and 2 Bas on both sides +n2 2 Apex, 2 Middle and 2 extra core from the	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. /% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer Gleason score 7 or above No. or % of positive cores	41,85%
			2 Apex, 2 Middle and 2 Bas on both sides +n2 2 Apex, 2 Middle and 2 extra core from the	traditional sextant (6- core), 4 lateral peripheral (10-core), 4 paramedian peripheral (14-core) and additional 4 lateral	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis)	41,85%

13	#1103	Ghafoori 2015			Positive pick-up rate (overall cancer diagnosis)		
	(see						
	complicatio						
	ns excel)				No./% of prostate cancer Gleason score 6		
					No. of clinically significant cancers (Gleason score 7 or above		
					No. or % of positive cores		
			X (60) X (60)		Positive pick-up rate (overall cancer diagnosis)	8 (13.3%)	21(35%)
					No./% of prostate cancer Gleason score 6		
			base, upper mic				
			mid and apex o				
			side + one from  base, upper mid, lower base and apex				
			nid and apex on both more medially a				
			side + one from middle more laterally +				
			pase and apex + one each segment +				
			more medially and one periurethral innore laterally (bilaterally)	er gland	No. of clinically significant cancers (Gleason score 7 or above		
			(onderdiny)		No. of chilically significant cancers (dieason score 7 of above		
1.4	401	Ironi 2042			No. or % of positive cores		
14	#91	Irani 2013			Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6		
					No. of clinically significant cancers (Gleason score 7 or above		
					No. or % of positive cores		
			169	166	Positive pick-up rate (overall cancer diagnosis)		71 (42%)
					No./% of prostate cancer Gleason score 6		
					No. of clinically significant cancers (Gleason score 7 or above		
					No. or % of positive cores		
15	#1343	Jiang 2016			Positive pick-up rate (overall cancer diagnosis)		
					No./% of prostate cancer Gleason score 6		
					No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores		
					No. of 76 of positive cores		
					Positive pick-up rate (overall cancer diagnosis)		
					No./% of prostate cancer Gleason score 6		
					No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores		
16	#1560	Leucona 2011			Positive pick-up rate (overall cancer diagnosis)		
					No./% of prostate cancer Gleason score 6		
					No. of clinically significant cancers (Gleason score 7 or above		
					No. or % of positive cores		
				152 (group A)	Positive pick-up rate (overall cancer diagnosis)	58 (38.4%)	
				157	No./% of prostate cancer Gleason score 6	9 (6%)	
						, ,	
				lateral peripheral zone	No. of clinically significant cancers (Gleason score 7 or above		
				iacerai periprierai zone	The state of the s		
				Vienna nomogram cores 10.2 (6-18)	No. or % of positive cores		
				2012 (0 20)	The state of the s		
33	#4164	Leitao 2017		ari	S Desitive nick up rate (everall ear	04/00 000	
33	#4164	Leitau 2017		431	Positive pick-up rate (overall cancer diagnosis)	84 (38.4%)	
					No./% of prostate cancer Gleason score 6		
	Nov search				No. of clinically significant cancers (Gleason score 7 or above		
	Jearen			237 (52%) on Vienna	Technically significant cancers (dicason score / or above		
				normogram group	No. or % of positive cores		
					Positive pick-up rate (overall cancer diagnosis)	I	

					No lot of seconds are second Classes are se		
					No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above		
					No. or % of positive cores		
17	#1582	Leibovici 2013			Positive pick-up rate (overall cancer diagnosis)		
					No./% of prostate cancer Gleason score 6		
					No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores		
					No. of 76 of postare cores		
			161		Positive pick-up rate (overall cancer diagnosis)		45 (24+17+4)
			155 ?		No./% of prostate cancer Gleason score 6		24
			3 Base, 3 mid, 3 apex +				
			lateral parallel locations, on both sides		No. of clinically significant cancers (Gleason score 7 or above		21
			on both sides		No. or % of positive cores		21
18	#1673	Lughezzani 2010			Positive pick-up rate (overall cancer diagnosis)		
					No./% of prostate cancer Gleason score 6		
					No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores		
					ino. or 70 or positive coles		
					Positive pick-up rate (overall cancer diagnosis)		
					No./% of prostate cancer Gleason score 6		
					No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores		
19	#1776	Miyoshi 2014			Positive pick-up rate (overall cancer diagnosis)		
					No./% of prostate cancer Gleason score 6		
					No. of clinically significant cancers (Gleason score 7 or above		
					No. or % of positive cores		
			195 195	137 137	332 Positive pick-up rate (overall cancer diagnosis)		
			155				
				137	No./% of prostate cancer Gleason score 6		
			8 cores from peripheral	8 cores from peripheral	No./% or prostate cancer Gleason score 6		
			zone + 4 cores from	8 cores from peripheral zone + 8 cores from			
				8 cores from peripheral	No. of clinically significant cancers (Gleason score 7 or above		
20	#1783	Mohammed 2016	zone + 4 cores from	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores		
20	#1783	Mohammed 2016	zone + 4 cores from	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6		
20	#1783	Mohammed 2016	zone + 4 cores from	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above		
20	#1783	Mohammed 2016	zone + 4 cores from	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6		
20	#1783	Mohammed 2016	zone + 4 cores from	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above		
20	#1783	Mohammed 2016	zone + 4 cores from	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above		
20	#1783	Mohammed 2016	zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores	43%	53%.
20	#1783	Mohammed 2016	zone + 4 cores from	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above  No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above	43%	53%
20	#1783	Mohammed 2016	zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)		
20	#1783	Mohammed 2016	zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)	43%	53% 66 (46%)
20	#1783	Mohammed 2016	zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)		
20	#1783	Mohammed 2016	zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above		
20			zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores	71 (50%)	66 (46%)
20	#1783	Mohammed 2016  Nomikos 2011	zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis)	71 (50%)	66 (46%)
20			zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6	71 (50%)	66 (46%)
20			zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis)	71 (50%)	66 (46%)
20			zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. or clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above	71 (50%)	66 (46%)
20			zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. or clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above	71 (50%)	66 (46%)
20			zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. or clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above	71 (50%)	66 (46%)
20			zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from transition zone	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 7 or above No. or % of positive cores	71 (50%)	66 (46%) 77 (54%)
20			zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from transition zone	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores	71 (50%)	66 (46%) 77 (54%)
20			zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from transition zone	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 7 or above No. or % of positive cores	71 (50%)	66 (46%) 77 (54%)
20			zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from transition zone  24 core: 136 (35.89%)  2 lat.bas, 3 lat mid, 3 apex, 2 parasagittal mid-	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 7 or above No. or % of positive cores	71 (50%)	66 (46%) 77 (54%)
20			zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from transition zone  24 core: 136 (35.89%)  2 lat.bas, 3 lat mid, 3 apex, 2 parasagittal midzone, 2 parasagital base	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 7 or above No. or % of positive cores No. or % of positive cores	71 (50%)	66 (46%) 77 (54%)
21			zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from transition zone  24 core: 136 (35.89%)  2 lat.bas, 3 lat mid, 3 apex, 2 parasagittal mid-	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer Gleason score 7 or above No. or % of positive cores  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  No. of positive cores	71 (50%)	66 (46%) 77 (54%)
21			zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from transition zone  24 core: 136 (35.89%)  2 lat.bas, 3 lat mid, 3 apex, 2 parasagittal midzone, 2 parasagital base	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 7 or above No. or % of positive cores No. or % of positive cores	71 (50%)	66 (46%) 77 (54%)
21	#1882	Nomikos 2011	zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from transition zone  24 core: 136 (35.89%)  2 lat.bas, 3 lat mid, 3 apex, 2 parasagittal midzone, 2 parasagital base	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores No. of of positive cores No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6	71 (50%)	66 (46%) 77 (54%)
21	#1882	Nomikos 2011	zone + 4 cores from transition zone	8 cores from peripheral zone + 8 cores from transition zone  24 core: 136 (35.89%)  2 lat.bas, 3 lat mid, 3 apex, 2 parasagittal midzone, 2 parasagital base	No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis) No./% of prostate cancer Gleason score 6 No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  No. of positive pick-up rate (overall cancer diagnosis)  No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  No. of clinically significant cancers (Gleason score 7 or above No. or % of positive cores  Positive pick-up rate (overall cancer diagnosis)	71 (50%)	66 (46%) 77 (54%)

				443 443 Positive pick-up rate (overall cancer diagno	297 (67%) 402 (90.7%)
				No./% of prostate cancer Gleason score 6	Low risk- 139 (47%)
				standard sextant	LOW 113A* 2.04 (30.770)
				biopsies + 6	
			standard sextant	posterolateral cores +	
			biopsies + 6 posterolateral cores	midline/transition zone	
			posterolateral cores	cores No. of clinically significant cancers (Gleason No. or % of positive cores	n score 7 or above Intermediate risk- 126 (42%); high risk- 32 (11%) Intermediate risk- 159 (39
23	#1968	Park 2010		Positive pick-up rate (overall cancer diagno	laise
				No./% of prostate cancer Gleason score 6	
				No. of clinically significant cancers (Gleaso	
				No. or % of positive cores	
			118	115 Positive pick-up rate (overall cancer diagno	usis) 40 (33.9%)
			γ 116	115 Positive pick-up rate (overall cancer diagnor Y No./% of prostate cancer Gleason score 6	
					(32.576)
			cores at apex middle and		
			base of right lateral, right	addition 3 cores from	
			medial, left medial and left lateral	each side between the	
			lett lateral	other groups  No. of clinically significant cancers (Gleason	n score 7 or above
		Rodriguez-		No. or % of positive cores	
24	#2124	Covarrubias 2011		Positive pick-up rate (overall cancer diagno	osis)
				No./% of prostate cancer Gleason score 6	
				No. of clinically significant cancers (Gleaso	n score 7 or above
				No. or % of positive cores	
			75	75 Positive pick-up rate (overall cancer diagno	usis) 23 (30.7%)
			73	73	25 (30.7%)
			75	75 No./% of prostate cancer Gleason score 6	13 (56.5%)
				6 cores from each lateral	
			6 cores from each lateral	lobe + 3 cores from the far lateral peripheral	
			lobe	zone of each lobe  No. of clinically significant cancers (Gleason	n score 7 or above 10 (43.4)
			1000	tone of contract (citation	10 (43.4)
				No. or % of positive cores	25,70%
25	#2210	Scattoni 2014		Positive pick-up rate (overall cancer diagno	
				No./% of prostate cancer Gleason score 6	
				No. of clinically significant cancers (Gleaso	
				No. or % of positive cores	
				Positive pick-up rate (overall cancer diagno	l sion
				No./% of prostate cancer Gleason score 6	
				No. of clinically significant cancers (Gleaso	
				No. or % of positive cores	
26	#2211	Scattoni 2010		Positive pick-up rate (overall cancer diagno	
				No./% of prostate cancer Gleason score 6	
				No. of clinically significant cancers (Gleason	a score 7 or above
				No. or % of positive cores	
				Positive pick-up rate (overall cancer diagno	
				No./% of prostate cancer Gleason score 6	
				No. of clinically significant cancers (Gleason No. or % of positive cores	I SCUTE / UT AUDUVE
27	#2213	Scattoni 2010		Positive pick-up rate (overall cancer diagno	osis)
				No./% of prostate cancer Gleason score 6	
				No. of clinically significant cancers (Gleaso	
				No. or % of positive cores	
					laia
				Positive pick-up rate (overall cancer diagno No./% of prostate cancer Gleason score 6	
				No./% of prostate cancer Gleason score 6  No. of clinically significant cancers (Gleason	
				No. or % of positive cores	
				not of the positive cores	

20	<b>#2200</b>	T 1 2045			I		
20	#2389	Tanaka 2015		Positive pick-up rate (overall cancer diagnosis)			
				No./% of prostate cancer Gleason score 6			
				No. of clinically significant cancers (Gleason score 7 or above			
				No. or % of positive cores			
			199	Positive pick-up rate (overall cancer diagnosis)	128 (75.7%) 170 (51.4%)	107 (45.1%)	44 (22.1%)
				Positive pick-up rate (overall caricer diagnosis)	170 (31.4%) 	107 (43.170)	44 (22.170)
				No./% of prostate cancer Gleason score 6			
				No. of clinically significant cancers (Gleason score 7 or above			
				No. or % of positive cores			
29	#2460	Tsivian 2012		Positive pick-up rate (overall cancer diagnosis)			
				No./% of prostate cancer Gleason score 6			
				No. of clinically significant cancers (Gleason score 7 or above			
				No. or % of positive cores			
				Positive pick-up rate (overall cancer diagnosis)			
				No./% of prostate cancer Gleason score 6			
				No. of clinically significant cancers (Gleason score 7 or above			
				No. or % of positive cores			
30	#2490	Ukimura 2013		Positive pick-up rate (overall cancer diagnosis)			
				No./% of prostate cancer Gleason score 6			
				No. of clinically significant cancers (Gleason score 7 or above			
				No. or % of positive cores			
				Positive pick-up rate (overall cancer diagnosis)			
				No /0/ of prostate concer Classon seems C			
				No./% of prostate cancer Gleason score 6			
				No. of clinically significant cancers (Gleason score 7 or above			
				No. of cliffically significant cancers (dieason score 7 of above			
				No. or % of positive cores			
31	#2685	Yoon 2012	123	Positive pick-up rate (overall cancer diagnosis)		93 (26.4%)	35 (28,4%) p= .378
			Not specified	No./% of prostate cancer Gleason score 6		NA	NA
			apex of the lateral				
			peripheral zone added to				
				No. of clinically significant cancers (Gleason score 7 or above		NA	NA
				No. or % of positive cores		NA	
				Positive pick-up rate (overall cancer diagnosis)		93 (26.4%)	35(28.4%)
				No./% of prostate cancer Gleason score 6			
			10 core sextant				
			technique + 2 from apex				
			of lateral PZ	No. of clinically significant cancers (Gleason score 7 or above			
				No. or % of positive cores			
32	#2712	Zavaski 2014		Positive pick-up rate (overall cancer diagnosis)			
				No./% of prostate cancer Gleason score 6			
				No. of clinically significant cancers (Gleason score 7 or above			
				No. or % of positive cores			
							_
				Positive pick-up rate (overall cancer diagnosis)			
				No./% of prostate cancer Gleason score 6			
				No. of clinically significant cancers (Gleason score 7 or above			
				No. or % of positive cores			

Numl	ber N	lumber	Author, year								Other. Please add any data you feel is interesting.	Conclusion / remarks
	c	Covidence		13 cores	14 cores	16 cores	18 cores	20 cores	21 cores	overall		
1			Abd 2011			•						
		ĺ	A00 2011									
2	#	774	Chambo 2014									
												No significant differences in cancer detection were found
						107						between the 3 groups.
						20						A 10-core biopsy is acceptable as a first biopsy.
												Additional biopsies should capture more lateral regions of
						67						the prostate
3	#	#924	Dell'Atti 2015									
												When PV increases, the core numbers should be increased
					198 (14.6%)		253 (18.6%)				Ned more study on PV+the number of cores?	in first PBx setting
					113		202					
					56 6,2		70 6,9					
4	#	983	Ekin 2015		0,2		0,5					
					147					147 (32.6%)		Gold standard for Pca dx is at least 8 cores  Although most dx was with 14 cores it is important to
					97							consider that these patients might have clinically insignificant PCa
												insignificant rea
					50 4,9							
5	#	1218	HerranzAmo 2010									
											Study stratified for prostate volume and showed for	
										86 (27.3%)	prostates over 50ml sextant biopsy insufficient (p=0.001)	
											Of 229 with benign pathology 116 (46.3%) had second	
										51 (59.3%)	biopsy which detected cancer in 13 (12.3%)	
6	#	796 (see	Chen 2016									
	(see complicatio ns excel)											
		- Chocij										

				They didn't perform a 10-core biopsy to any patient. They assumed cancer detection rate of 10-core	
					Detection rate of prostate cancer enhances with increasing
				and 13-core biopsies.	PSA level and decreaes with accruing prostate volume;
			20 (1020)		10- and 13-core biopsies have similar yield in both positive
					detection rate and percentage of positive cores,, however
					10-core biopsy have lower risk of complications
					(hematuria).
					A 42 bi b b d b d-i d d
					A 13-core biopsy should not be advised to detect prostate cancer.
					cancer.
7	#788	Chen 2012			
,	#700	CHEH 2012			
					42 bi
					12 core biopsy recommended
9	#854	Cormio 2014			
	(see				
	complicatio				
	ns excel)				
				The study only have 1 group of patients. All of them	
				underwent 18-core biopsies and at the end, based on	
				the location of prostate cancer detetion the authors	
				assumed the ideal number of cores based on their	10-core protocol improves detection ates at fist biopsy
			26 2 452	potocol.	compared to 6-cores.
			20 2 432		
			20 2 432		Adding lateral peripheral cores did not improve cancer
			20 2 432		
			20 2 472		Adding lateral peripheral cores did not improve cancer
			20 2 4,72		Adding lateral peripheral cores did not improve cancer
			20 2 3,2		Adding lateral peripheral cores did not improve cancer detection rates at first biopsy
			20 2 4,52		Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a
			20 2 4,22		Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients'
			20 2 3,2		Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a
					Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant
					Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.
11	#992	Elshafei 2014	46,24%		Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and
11	#992	Elshafei 2014			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and
					Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and
risk and 5 i	the higher ris	isk group			Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and
	n the higher ris		46,24%		Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and
risk and 5 i	the higher ris	isk group	46,24%		Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and
risk and 5 i	the higher ris	isk group	46,24%		Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and
risk and 5 i	the higher ris	isk group	46,24%		Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and
risk and 5 i	the higher ris	isk group	46,24%  3 (2 - 6) 3 in the standard risk and 3 in the higher risk group		Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and
risk and 5 i	the higher ris	isk group	46,24%  3 (2 - 6) 3 in the standard risk and 3 in the higher risk group	This study doesn't answer to PICO 1	Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and
risk and 5 i	the higher ris	isk group	46,24%  3 (2 - 6) 3 in the standard risk and 3 in the higher risk group		Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and
risk and 5 i	the higher ris	isk group	46,24%  3 (2 - 6) 3 in the standard risk and 3 in the higher risk group		Adding lateral peripheral cores did not improve cancer detection rates at first biopsy  Adding 4 paramedian peripheral samples, fail to provide a statistically significant advantage in the overall patients' population, however provided a statistically significant increase in cancer detection rate in patients with low PSA density.  In the high risk group, there were significantly different between 12 and 14 core, not in the standard group  When stratified by risk according to pre-biopsy clinical criteria, they believe that the 14 core scheme is most beneficial in patients with an elevated PSA>2.5ng/ml and

13	#1103	Ghafoori 2015			
	(see				
	complicatio ns excel)				
	, , ,				
			24 (40%)	Complications recreased from 12 to 18 core	From 6 to 12 cores increased canser detection rate
					Rom 12 to 18 core biopsy resulted in no statistically
					significant difference for detection of canser, but the infection increased.
					12 core biopsy approach seems to have optimum balance
					between the cancer detection rate and biopsy
14	#91	Irani 2013			complications.
				Complications including pain using VAS, fever at day 5 and Haematuria, haematospermia nad recta bleeding	
				at day 5 and 15 were recorded but no differences	
			81 (48.8%) 152 (45.4%)	noted excepted increased urinary discomfort at 5 days in the extended group.	
				5 T T T T T T T T T T T T T T T T T T T	
15	#1343	Jiang 2016			
				Meta-analysis not related to PICO 1 but can be very interesting for writting this chapter	
				interesting for writting and enapter	
16	#1560	Leucona 2011			
				group A: no. of cores varies according to Vienna	No significant differences were found between cancer
			group A: 54 (35.5%)	nomogram	detection using Vienna nomogram or 8-core biopsy
					there is no significant advantage in using the Vienna
			20012A+F /2 20/\	group B: 8-core biopsy	nomogram to determine the number of prostate biopsy cores to be taken, compared to an 8-core biopsy protocol.
			groupA: 5 (3.3%)	group B. o core biopsy	cores to be taken, compared to an o core slopsy protocos.
					The use of the Vienna Nomogram compared with a 10-core
				biopsies according to Vienna Nomogram and the article doesn't specifies number of cores taken in this	biopsy protocol does not significantly increase the overall prostate cancer detection rate. No significant difference
33	#4164	Leitao 2017	Vienna normogram: 101		was found.
	Nov search				
					No significant difference in the overall cancer detection
					rate between both groups. Cancer detection rate increase
					in both groups with the age of patients. In both groups, decrease of detection rate with increase of prostate
			Group B (10 cores): 38.49	. Group A (Vienna nomogram): 42.6%. p= .705 (NS). Wh	volume but study could be underpowered.

17	#1582	Leibovici 2013			
					Patients with positive biopsy tended to have smaller prostates than patients with neg biopsy.
					12 core may be insufficient for prostates larger than 72 ml
18	#1673	Lughezzani 2010			
					Systematic-review not related to PICO 1 but can be
					interesting for writting this chapter
19	#1776	Miyoshi 2014			
		Mohammed 2016			
				Excluded (transperineal biopsies)- not for PICO 1	
20	#1783				
				group A: 6-core	12-core biopsies are associated with higher PCa cancer detection rates, greater accuracy for Gleason grading and no differences for detecting clinically insignificant PCa compared to 6-core biopsies.
					12-core biopsies are not associated with a higher rate of
				group B: 12-core	post biopsy complications compared to 6-core biopsies
21	#1882	Nomikos 2011			
			24 cores: 34.55%	24 cores	24 cores did not show any benefit vs. 10 cores
22	#1931	Ouzaid 2013			
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	2 220.0 2013			

			41 (9.2%) Mean 4 (1-21)	There was only 1 group of patients and all of them were submitted to 21-cores biopsy. The authors assumed cancer detection rate related to 6 and 12-cores only based on localization of the cores.	This study invalidates the widespread idea sustaining that cancers diagnosed by more than 12 biopsies are less aggressive
			Low risk- 24 (58%)	If a patient had diferent site of PCa, the patient was sorted according to the 1rst positive site.	
.6%) high	risk- 39 (9.7%)		Intermediate risk- 14 (35%) high risk- 3 (7%) 41,70%	It seems hat if we extend the number of cores to 21 we mainly find low risk prostate cancer	
23	#1968	Park 2010			
			49 (42.6%) 23 (47%)	Assessed detection rate with regard to prostate volume and PSAD. Suggested 18 core protocol effective is PSAD 0.15 -0.25	
24	#2124	Rodriguez- Covarrubias 2011			
			36 (48%)	group A: 12-core	18-core biopsies improves PCa detection, does not increase morbidity but may increase the detection of clinically insignificant cancer.
			21 (58.3%)	group B: 18-core	12-core biopsies are adequate for PCa detection (at least a first biopsy).
			· ·		
			15 (41.7%)		
			24,30%		
25	#2210	Scattoni 2014			
				SPBx seems to be necessary in some cases, mostly when PSA < 10 ng/ml and in repeat setting.	I'm not sure if it answer to PICO 1, but it's seems important to the guidlines.
26	#2211	Scattoni 2010			
					PBx schemes are evolving also because the scenario in which a PBx is necessary is changing. Random prostate PBs do not represent the future, while imaging target biopsy are becoming more popular. However, there is now a growing evidence in the literature that (a) saturation PBx (>20 cores) (SPBx) might be indicated in patients with PSA <10 ng/ml or low PSA density or large prostate and (b) an individualized approach with more than 12 cores according to the clinical characteristics of the patients may optimize cancer detection in the single patient.
27	#2213	Scattoni 2010			

28	#2389	Tanaka 2015			
					Cancer detection using NURTG normogram performing 6, 8, 10 or 12-core biopses according to the relation between
					the age and prostate volume is similar compared with
			449 patients	group A: all patients	more expanded number of biopsy cores
			143 (32%)	group B: no cancer group	In older patients the number of cores can be reduced.
			304 (68%)	group C: cancer group	
29	#2460	Tsivian 2012			
					Biopsy accuracy in identifying unilateral prostate cancer
				They compare 6 - 9 cores (sextant) to 10 - 20 cores (extended)	depends on prostate weight. The number of cores may be extended in prostate more than 40 g.
				This study is only from patients diagnosed with CaP	extended in prostate more than 40 g.
				and operated RARP	
30	#2490	Ukimura 2013			
					A summary of contemporary recommendations (Table 3)
					supports a 10- to 12-core extended PB scheme, with
					additional cores from areas suspected by DRE or TRUS.
					Figure 1 indicates the recommended biopsy location and
					direction of a typical transrectal 12-core biopsy template to
					maximise the sampling from the PZ (without the distal end of the needle into the TZ). Repeated bx: Recognising the
					inherent potential for a systematic biopsy to miss (usually)
					small-volume cancers, a significant number of men will undergo repeat PB.
					unueigo repeat ro.
31	#2685	Yoon 2012			
			(128)27%		
32	#2712	Zavaski 2014			
					1
				The authors only mention no. of cores related to	
				forecast of final tumor volume.	